1 - 16 of 16
Establishes a set of definitions, policies, and procedures to guide the involvement of individuals such as long-term collaborators, high school and college-level students, graduate students, and others who are not regular CHOP employees in the Research Institute’s programs.
Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation, and she is the principal investigator of ongoing hemophilia A and B gene therapy trials.
Dr. Glatz is a pediatric interventional cardiologist conducting rigorously designed clinical research. He has formal Masters-level training in study design, epidemiology, and biostatistics. Dr. Glatz has an extensive record of research productivity, including multiple collaborative projects, focused on outcomes research in the content area of pediatric cardiology.
Dr. Gmuca seeks to enhance the care of children with chronic musculoskeletal pain. Her current research addresses amplified musculoskeletal pain syndrome, which is a major public health issue because of its high prevalence, related socioeconomic burden, and associated risk of opioid exposure. Dr. Gmuca’s work aims to identify innovative strategies to improve long-term treatment outcomes for this patient population.
Dr. Gonzalez-Alegre's long-range research goal is to advance the application of precision medicine in the neurology clinic. His research focus revolves around genetic disorders that affect the brain, spanning from the diagnosis of novel genetic disease in the clinic to the identification of novel molecular targets using disease models and the design of early-phase human clinical trials.
Dr. Graci aims to identify the mechanisms underlying injury to inform strategies and interventions to reduce injury and improve safety. She leverages her eclectic scientific background, spanning from experimental psychology to exercise science and biomechanics. Her research focuses on biomechanical risk factors for age-related falls, and injury mechanisms due to motor vehicle accidents.
Dr.Grundmeier’s research focuses on maximizing the existing and future potential of electronic health records (EHRs) for clinical research and knowledge delivery, with an overarching goal of improving health and healthcare for children.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
Dr. Guevara is the principal investigator on research grants evaluating health inequities in early childhood development and behavioral problems. He utilizes community-based participatory clinical trials involving parent advocacy groups, community organizations, and government agencies to test the effects of psychosocial interventions designed to provide parents with resources and tools to improve the care of their children.